Brief: Carsgen Therapeutics Says Collaboration Agreement For Zevorcabtagene- Autoleucel

CARsgen Therapeutics Holdings

16/01/2023 12:13

Jan 16 (Reuters) - CARsgen Therapeutics  2171.HK :
    * COLLABORATION AGREEMENT FOR ZEVORCABTAGENE- AUTOLEUCEL
WITH
HUADONG MEDICINE
    * UNIT  ENTERED COLLABORATION AGREEMENT WITH HUADONG
MEDICINE
    * UNDER AGREEMENT, CARSGEN WILL RECEIVE AN UPFRONT PAYMENT
OF
RMB200 MILLION
    * DEAL FOR COMMERCIALIZATION OF CARSGEN'S LEAD DRUG
CANDIDATE,
ZEVORCABTAGENE AUTOLEUCEL IN MAINLAND CHINA
    * CARSGEN WILL CONTINUE TO BE RESPONSIBLE FOR DEVELOPMENT,
REGULATORY APPROVAL, AMONG OTHERS OF CT053 IN MAINLAND CHINA
    * UNDER AGREEMENT, CARSGEN IS ELIGIBLE TO RECEIVE REGULATORY
AND
COMMERCIAL MILESTONE PAYMENTS UP TO RMB1,025 MILLION

Further company coverage:  2171.HK 
 ((Reuters.Briefs@thomsonreuters.com;))